Article ; Online: Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
Breast cancer research and treatment
2024 Volume 205, Issue 1, Page(s) 201–210
Abstract: Purpose: In 2010, the US Food and Drug Administration approved eribulin for the treatment of metastatic breast cancer (MBC). Since then, the treatment landscape has evolved with many new therapy classes, a more recent one being the small molecule ... ...
| Abstract | Purpose: In 2010, the US Food and Drug Administration approved eribulin for the treatment of metastatic breast cancer (MBC). Since then, the treatment landscape has evolved with many new therapy classes, a more recent one being the small molecule inhibitors of phosphoinositide 3 kinase (PI3K). We sought to characterize the treatment patterns and clinical outcomes of patients with MBC who received eribulin following prior treatment with a PI3K inhibitor. Methods: A retrospective cohort study based on medical record review included MBC patients who initiated eribulin between March 2019 and September 2020 following prior treatment with a PI3K inhibitor was conducted. Patient demographics, treatment characteristics, and clinical outcomes were analyzed descriptively. Real-world progression-free survival (rwPFS) and overall survival (OS) were estimated from the initiation of eribulin therapy using Kaplan-Meier analyses. Results: 82 eligible patients were included. Patients' median age at eribulin initiation was 62 years; 86.5% had hormone receptor-positive, human epidermal growth factor receptor 2-negative tumors. Eribulin was most often administered in the second or third line (82.9%) in the metastatic setting. Best overall response on eribulin was reported as complete or partial response in 72% of the patients. The median rwPFS was 18.9 months (95% confidence interval [CI], 12.4-not estimable); median OS was not reached. The estimated rwPFS and OS rates at 12 months were 63.3% (95% CI, 50.5-73.7) and 82.6% (95% CI, 72.4-89.3), respectively. Conclusion: Our real-world study suggests that eribulin may be a potential treatment option for MBC patients who fail a prior PI3K inhibitor. |
|---|---|
| MeSH term(s) | Humans ; Furans/therapeutic use ; Ketones/therapeutic use ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Breast Neoplasms/mortality ; Middle Aged ; Aged ; Retrospective Studies ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Adult ; Neoplasm Metastasis ; Treatment Outcome ; Aged, 80 and over ; Polyether Polyketides |
| Chemical Substances | eribulin (LR24G6354G) ; Furans ; Ketones ; Phosphoinositide-3 Kinase Inhibitors ; Polyether Polyketides |
| Language | English |
| Publishing date | 2024-02-04 |
| Publishing country | Netherlands |
| Document type | Journal Article |
| ZDB-ID | 604563-7 |
| ISSN | 1573-7217 ; 0167-6806 |
| ISSN (online) | 1573-7217 |
| ISSN | 0167-6806 |
| DOI | 10.1007/s10549-023-07080-1 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1655: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.